Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The goal of this single-center, prospective clinical trial is to test the safety and efficacy
of belimumab combined with multi-target therapy in the treatment of severe lupus nephritis.
The main questions it aims to answer are: lupus nephritis complete remission rate at week 24,
and the partial remission rate and safety assessments. Patients with severe lupus nephritis
will be enrolled and received pulse methylprednisolone at a dose of 1.5 to 3.0g, followed by
intravenous belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks
thereafter. Multitarget therapy will be also administered during the induction phase.
Induction therapy will last for 24 weeks. Patients with severe lupus nephritis who only
received multi-target therapy during the same period will be enrolled as the control group.